Metotrexate Ebewe

Methotrexate, the active ingredient in Metotrexate Ebewe, is a Antimetabolite (Folate antagonist) presented as a sterile injectable solution for Intramuscular, Intravenous, Subcutaneous use. It is employed to treat rheumatoid arthritis, psoriasis, and several malignancies in adult patients.

GNH USA supplies Metotrexate Ebewe as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Methotrexate is used across autoimmune and oncologic disease pathways to inhibit abnormal cell proliferation. - Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: diminishes skin lesions and plaque formation. - Acute lymphoblastic leukemia: eradicates rapidly dividing leukemic blasts. - Non‑Hodgkin lymphoma: impedes lymphoma cell growth. - Gestational trophoblastic disease: promotes resolution of abnormal trophoblastic tissue.

Methotrexate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset occurring shortly after administration. - Stomatitis: inflammation and ulceration of the oral mucosa. - Fatigue: generalized tiredness and reduced energy. - Elevated liver enzymes: mild hepatic enzyme rise detectable on labs. - Mild cytopenias: slight reductions in white blood cells or platelets.

Serious or Rare Side Effects: - Severe hepatotoxicity: potential liver injury requiring monitoring. - Pulmonary fibrosis: interstitial lung disease presenting with cough and dyspnea. - Myelosuppression: profound bone‑marrow suppression leading to infection risk. - Renal toxicity: impaired kidney function, especially with high doses. - Severe mucositis: extensive oral and gastrointestinal ulceration. - Anaphylaxis: rare hypersensitivity reaction requiring immediate medical attention.

Methotrexate requires careful monitoring and patient education to minimize risks. - Pregnancy: contraindicated (Category X); teratogenic effects can be fatal to the fetus. - Renal function: assess creatinine clearance before each dose; adjust or avoid if impaired. - Hepatic function: perform baseline and periodic liver function tests; avoid in severe liver disease. - Hematologic monitoring: regular complete blood counts to detect myelosuppression. - Concomitant NSAIDs: use with caution as they may increase toxicity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate interacts with several drug classes that can alter its efficacy or safety.

Major Interactions (Avoid): - Live vaccines: may cause severe infection due to immunosuppression. - NSAIDs (e.g., ibuprofen, naproxen): increase risk of renal toxicity and gastrointestinal ulceration. - Penicillins (e.g., ampicillin): potentiate myelosuppression.

Moderate Interactions (Monitor Closely): - Sulfonamides and trimethoprim: may enhance hematologic toxicity. - Proton pump inhibitors: can raise methotrexate plasma levels. - Azathioprine or other immunosuppressants: additive bone‑marrow suppression. - Vitamin supplements containing folic acid: may reduce therapeutic effect; dosing should be coordinated with prescriber.